Dongwha Pharm Co Ltd
KRX:000020

Watchlist Manager
Dongwha Pharm Co Ltd Logo
Dongwha Pharm Co Ltd
KRX:000020
Watchlist
Price: 6 190 KRW -0.32% Market Closed
Market Cap: 172.9B KRW

Relative Value

The Relative Value of one Dongwha Pharm Co Ltd stock under the Base Case scenario is 11 157.2 KRW. Compared to the current market price of 6 190 KRW, Dongwha Pharm Co Ltd is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
11 157.2 KRW
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
93
vs Industry
86
Median 3Y
0.6
Median 5Y
0.8
Industry
2.6
Forward
0.4
vs History
19
vs Industry
22
Median 3Y
16.1
Median 5Y
16.1
Industry
21.4
Forward
4.4
vs History
vs Industry
41
Median 3Y
7.2
Median 5Y
8.1
Industry
16.4
vs History
vs Industry
5
Median 3Y
-4.6
Median 5Y
14.5
Industry
22.8
vs History
92
vs Industry
76
Median 3Y
0.6
Median 5Y
0.7
Industry
2.2
vs History
58
vs Industry
86
Median 3Y
0.5
Median 5Y
0.5
Industry
2.9
Forward
0.6
vs History
47
vs Industry
83
Median 3Y
1
Median 5Y
1.1
Industry
5.5
vs History
15
vs Industry
40
Median 3Y
6.9
Median 5Y
7
Industry
13
Forward
4.3
vs History
7
vs Industry
20
Median 3Y
16.1
Median 5Y
12.7
Industry
16.5
Forward
5.4
vs History
vs Industry
45
Median 3Y
4.3
Median 5Y
5.5
Industry
15.6
vs History
vs Industry
12
Median 3Y
-2.3
Median 5Y
12.3
Industry
18.7
vs History
76
vs Industry
78
Median 3Y
0.4
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Dongwha Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Dongwha Pharm Co Ltd
KRX:000020
171.6B KRW 0.4 27.1 9.2 47.6
US
Eli Lilly and Co
NYSE:LLY
985.1B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.6B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
259.3B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 4.9 30.3 108.9 159.3
US
Merck & Co Inc
NYSE:MRK
267.2B USD 4.2 14 10 11.8
CH
Novartis AG
SIX:NOVN
210.7B CHF 4.8 18.5 11.7 15.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.8 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.1B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
KR
Dongwha Pharm Co Ltd
KRX:000020
Average P/E: 24.5
27.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.3
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
CH
Novartis AG
SIX:NOVN
18.5
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Dongwha Pharm Co Ltd
KRX:000020
Average EV/EBITDA: 400.6
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
CH
Novartis AG
SIX:NOVN
11.7
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Dongwha Pharm Co Ltd
KRX:000020
Average EV/EBIT: 1 716.5
47.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5